Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:

GSK Set To Begin Trials On Japan’s Third Bird-Flu Vaccine

This article was originally published in PharmAsia News

  • News

Executive Summary

Japan's Health Ministry gave GlaxoSmithKline fast-track status for its bird-flu vaccine, clearing the way for clinical trials to begin as early as this year. If successful, the GSK pre-pandemic vaccine against the H5N1 flu virus would be the third approved for marketing in Japan, which already has stockpiled enough doses for 20 million people. GSK has approval for its vaccine in the European Union. The medical community would like to have as many choices of vaccines as possible because of uncertainties surrounding a possible pandemic of the virus. (Click here for more - a subscription may be required
Table

View full table

Advertisement
Advertisement
Tags:
UsernamePublicRestriction

Register

SC069396

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By